Cargando…

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells

Pancreatic cancer is characterized by mutated signaling pathways and a high incidence of drug resistance. Comprehensive, large-scale proteomic analysis can provide a system-wide view of signaling networks, assist in understanding drug mechanisms of action and interactions, and serve as a useful tool...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xu, Shen, Xiaomeng, Qu, Jun, Straubinger, Robert M., Jusko, William J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827530/ https://www.ncbi.nlm.nih.gov/pubmed/29520231 http://dx.doi.org/10.3389/fphar.2018.00084

Ejemplares similares

Multi‐Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
por: Miao, Xin, et al.
Publicado: (2016)

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
por: Niu, Jin, et al.
Publicado: (2020)

Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer
por: Lin, Qingxiang, et al.
Publicado: (2022)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer
por: Yao, Jingjing, et al.
Publicado: (2022)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy
por: Liew, Hui Shan, et al.
Publicado: (2022)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
por: Fichtner, Michael, et al.
Publicado: (2020)

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2023)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

Thymoquinone affects the gemcitabine sensitivity of pancreatic cancer by regulating collagen via hypoxia inducible factor-1α
por: Zhao, Zhanxue, et al.
Publicado: (2023)

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
por: Xiao, Zhijun, et al.
Publicado: (2021)

β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
por: Cao, Zhang-qi, et al.
Publicado: (2019)

A Multidimensional Bayesian Network Meta-Analysis of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Gemcitabine and Cisplatin
por: Ni, Mengwei, et al.
Publicado: (2021)

Corrigendum: β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-Pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
por: Cao, Zhang-qi, et al.
Publicado: (2020)

Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
por: Morrish, Emma, et al.
Publicado: (2020)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP
por: Zhao, Li, et al.
Publicado: (2017)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
por: Huang, Jun-Hao, et al.
Publicado: (2023)

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells
por: Lin, Lanke, et al.
Publicado: (2023)

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

Modeling HIV Pre-Exposure Prophylaxis
por: Straubinger, Thomas, et al.
Publicado: (2020)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma
por: He, Hua, et al.
Publicado: (2022)

Inhibitory effect of baicalein combined with gemcitabine in human pancreatic cancer cell lines
por: Li, Zhenlei, et al.
Publicado: (2018)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
por: Ding, Jun, et al.
Publicado: (2020)

Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo
por: Shi, Yuqi, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fkcem0jkr1agsj3i86e5fkth7m